IDEXX Laboratories, Inc. Stock
Equities
IDXX
US45168D1046
Medical Equipment, Supplies & Distribution
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
548.5 USD | +5.26% | +12.62% | -1.17% |
05-14 | Morgan Stanley Adjusts Price Target on IDEXX Laboratories to $596 From $620 | MT |
05-02 | BNP Paribas Adjusts Price Target on IDEXX Laboratories to $641 From $653 | MT |
Sales 2024 * | 3.94B 5.37B | Sales 2025 * | 4.34B 5.91B | Capitalization | 43.04B 58.55B |
---|---|---|---|---|---|
Net income 2024 * | 923M 1.26B | Net income 2025 * | 1.04B 1.41B | EV / Sales 2024 * | 11 x |
Net Debt 2024 * | 396M 538M | Net Debt 2025 * | 223M 303M | EV / Sales 2025 * | 9.96 x |
P/E ratio 2024 * |
47
x | P/E ratio 2025 * |
41.6
x | Employees | 11,000 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 76.19% |
Latest transcript on IDEXX Laboratories, Inc.
1 day | +5.26% | ||
1 week | +12.62% | ||
Current month | +11.32% | ||
1 month | +11.65% | ||
3 months | -3.57% | ||
6 months | +19.10% | ||
Current year | -1.17% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 63 | 12-07-31 | |
Brian McKeon
DFI | Director of Finance/CFO | 61 | 03-06-30 |
John Hart
COO | Chief Operating Officer | - | 07-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Daniel Junius
BRD | Director/Board Member | 71 | 14-03-10 |
M. Szostak
BRD | Director/Board Member | 73 | 12-07-15 |
Chairman | 61 | 16-10-18 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
8.32% | 1 M€ | -.--% | ||
1.59% | 17 M€ | +7.01% | - | |
1.14% | 2 M€ | -1.17% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-14 | 521.1 | +3.60% | 636,588 |
24-05-13 | 503 | -1.33% | 374,410 |
24-05-10 | 509.8 | +1.80% | 526,504 |
24-05-09 | 500.8 | +2.82% | 546,581 |
24-05-08 | 487.1 | +0.70% | 604,652 |
Delayed Quote Nasdaq, May 15, 2024 at 04:00 pm
More quotesEPS Revisions
- Stock Market
- Equities
- IDXX Stock